MEK is among the most common targets in the MAPK pathway, but MEK inhibitors have been largely disappointing in this context, proving to be of a very limited activity in patients with lung adenocarcinoma harbouring KRAS mutations [58]. This evidence concerns the gene MAP2K7 and lung adenocarcinoma.